A Hepatitis C Sentinel Seroprevalence, Cape Coast, Ghana

Abstract

Objectives: Sentinel studies have targeted prenatal women as they are largely descriptive of the reproductive bracket, and prevalence data may be extended to the general population. This study determined the seroprevalence of hepatitis C virus (HCV) infection among pregnant women attending antenatal clinic at the Cape Coast Metropolitan Hospital. Methods: Whole blood samples were collected from 258 pregnant women aged between 15-45 years, from September 1st through December 31st, 2018. Separated plasma was stored and later screened for HCV antibodies. Results: Out of the total, 2.7% (7/258) tested seropositive for HCV antibodies. The 20 - 29 years age group recorded the highest prevalence of 1.6% (4/258, χ2 = 4.260, p = 0.513). According to the 2018 HIV Sentinel Surveillance report, the prevalence of HIV infection in the Cape Coast Metropolitan Area was 3.4% (17/500). Also, the prevalence of HIV among the 20-29 years age group was 1.8% (9/500). The 15-24 years, proxy group for new infections recorded 0.8% (2/258) for HCV and 0.2% (1/500) for HIV infection. Conclusions: The seroprevalence determined in this study is classified ‘intermediate,’ according to the WHO guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. The WHO currently does not recommend routine HCV testing for pregnant women; however, this study highlights the need for urgent public health interventions aimed at reducing the infection rate. J Microbiol Infect Dis 2020; 10(1):52-55.

Keywords

• Hepatitis C
• Sentinel
• Pregnant women
• Antenatal screening
• Seroprevalence

References

1. 1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17(2): 107-115. 2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244 (4902): 359-362. 3. Mutagoma M, Balisanga H, Sebuhoro D, et al. Hepatitis C virus and HIV co-infection among pregnant women in Rwanda. BMC infectious diseases 2017; 17(1): 167. 4. Kopilović B, Poljak M, Seme K, Klavs I. Hepatitis C virus infection among pregnant women in Slovenia: study on 31,849 samples obtained in four screening rounds during 1999, 2003, 2009 and 2013. Eurosurveillance 2015; 20(22): 21144. 5. Agyeman AA, Ofori-Asenso R, Mprah A, Ashiagbor G. Epidemiology of hepatitis C virus in Ghana: a systematic review and meta-analysis. BMC infectious diseases 2016; 16(1): 391. 6. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization 2018; Licence: CC BY-NC-SA 3.0 IGO. 7. Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am Journal of Gastroenterology 1991; 86(3): 335-338. 8. The Global burden of Hepatitis C working Group Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20–29. 9. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol 2020; 72(2):250-261. 10. Blasig A, Wagner EC, Pi D, et al. Hepatitis C infection among pregnant women in British Columbia: reported prevalence and critical appraisal of current prenatal screening methods. Canadian J Public Health 2011; 102(2): 98-102. 11. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27(1):108-117. 12. Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses 2012; 4:3531-3550. 13. Barral MF, Oliveira GR, Lobato RC, Mendoza-Sassi RA, Martínez AM, Gonçalves CV. Risk factors of HIV-1 vertical transmission (VT) and the influence of antiretroviral therapy (ART) in pregnancy outcome. Revista do Instituto de Medicina Tropical de São Paulo 2014; 56(2):133-138. 14. Labarga P, Pinilla J, Cachorro I, del Prado YR. Infant of 22 months of age with no anomalies born from a HCV-and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. Reproductive Toxicology 2007; 1; 24(3-4):414-416. 15. Toussaint-Miller KA, Andres J. Treatment considerations for unique patient populations with HCV genotype 1 infection. Annals of Pharmacotherapy. 2015; 49(9):1015-1030.